Strata Oncology’s Post

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study RESULTS PFS was significantly improved with D CT versus CT (hazard ratio [HR], 0.74; 95% CI, 0.62 to 0.89; P = .0009; median, 5.5 v 4.8 months); a trend for improved OS did not reach statistical significance (HR, 0.86; 95% CI, 0.72 to 1.02; P = .0758; median, 13.3 v 11.7 months; 24-month OS, 29.6% v 22.1%). PFS (HR, 0.72; 95% CI, 0.60 to 0.86; P = .0003; median, 6.2 v 4.8 months) and OS (HR, 0.77; 95% CI, 0.65 to 0.92; P = .0030; median, 14.0 v 11.7 months; 24-month OS, 32.9% v 22.1%) were significantly improved with T D CT versus CT. Treatment-related adverse events were maximum grade 3/4 in 51.8%, 44.6%, and 44.4% of patients receiving T D CT, D CT, and CT, respectively; 15.5%, 14.1%, and 9.9%, respectively, discontinued treatment because of treatment-related adverse events. CONCLUSION D CT significantly improved PFS versus CT. A limited course of tremelimumab added to durvalumab and chemotherapy significantly improved OS and PFS versus CT, without meaningful additional tolerability burden, representing a potential new option in first-line mNSCLC. https://lnkd.in/grhWjAcW

#DaiichiSankyo and #AstraZeneca continuing to advance treatment for Metastatic HER2 Positive Tumors. ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications with the latest in HER2 expressing (IHC 3 ) metastatic cancers

👏 This is fantastic news. As someone with HER2 positive stage 4 clear cell ovarian cancer this is the next step for me. I can’t wait to see approval granted for ovarian cancer here in Australia 🤞. 🧬 “As the first antibody drug conjugate to be granted a tumor agnostic indication”… this approval “also elevates the importance of testing for biomarkers, including HER2, across a broad range of tumors to ensure these patients with advanced cancer who have few options know whether a targeted medicine might be right for them.” 🔬 Genetic testing of tumour tissue, real time oncology review, precision medicine, and accelerated approval of life extending tumour agnostic treatments, is dramatically changing the cancer care landscape. 🙏Thank you Daiichi Sankyo and AstraZeneca for leading the charge with HER2-ADCs! #genomics #clinicaltrials #cancerresearch #precisionmedicine #cancercare #sciencesaveslives #ovariancancer #rarecancer #closethecaregap

SCLC breakthrough therapy from #Amgen: The FDA's approval of IMDELLTRA™ (tarlatamab-dlle) for extensive-stage small cell lung cancer (ES-SCLC) is groundbreaking, marking the first T-cell engager therapy for this disease. With a 40% response rate and a 14.3-month median overall survival in the pivotal DeLLphi-301 study, this approval is especially significant for me, as my postdoctoral research focuses exclusively on SCLC drug development. #sclc #cancertreatment #drugdevelopement #Drugdiscovery

PD-L1 has become one of the most important decision-making tools available to physicians when deciding on an optimal treatment approach for their NSCLC patients. In their latest article, Ipsos’ oncology experts use Global Oncology Monitor data to explore the possibility that physician interpretation of PD-L1 expression in NSCLC may not always be clear-cut – and the impact this ambiguity may be having on treatment choice… Read the article here: https://lnkd.in/espX7QEa #ipsosoncology #nsclc #immunotherapy

#ICYMI: In the search for new #oncology treatments, potential #therapies have emerged focused on the novel target Claudin 6 (CLDN6). T cell engager assets, including Context's CTIM-76, highlight CLDN6-targeted therapeutic modalities that could enhance the treatment of CLDN6-positive solid #tumors, including ovarian, lung, and testicular. Read more in this BioPharma Dive article. https://lnkd.in/eSp_J_Vm  

Urgency around advancement in precision oncology... This article outlines critical aspects of cancer care, which are truly impacting patient outcomes, and highlights the need for patient education on the importance of biomarker testing and empowering patients to understand their role in advocating for personalized treatment. We must join forces in partnerships to recognize that patient-centric diagnostics using robust genetic and molecular biomarker data can revolutionize the landscape of precision oncology care. My STRONG and VIBRANT MOM, diagnosed with stage IV #lungcancer as an "incidental finding", asymptomatic, non-smoker, with EGFR mutation, is a case study. We are currently searching desperately for novel #clinicaltrials after Osimertinib resistance, which is common, despite the amazing results of this AstraZeneca TKI. We urgently need more lines of tx, which requires more #researchstudies and patient participation in #clinicaltrials . Patients only know what they know, so partnerships like with LUNGevity Foundation, are a critical piece to reaching patients where they are and educating, empowering, and providing access! Thank you, Omar Perez Mohit Manrao #precisiononcology #egfr #patientoutcomes #biomarkertesting #oncology #cancercare #lungcancerawareness #patientcentric #pfdd #patientfocused #oncologyeducation #biopharma #tagrisso #osimertinib Dana-Farber Cancer Institute Upal Basu Roy, PhD, MPH Jill Feldman

#BreakingNews: Our HER2 directed medicine is the first of its kind to receive a tumor agnostic indication in the U.S. This accelerated approval is a pivotal moment for certain previously treated patients with HER2 positive tumors who have had limited treatment options. Click the image for more information on this approval and what it means for patients. #Oncology #FDA

This treatment efficacy evaluation method for solid tumors is on the way to introduce a fundamental change in the treatment decision. Combined to liquid biopsy, the ctDNA analysis seems to correlate with the most important end point, Overall Survival. In addition to be a minimally invasive method, this assessment is not limited in frequency compared to the radiographic evaluation, what facilitates its integration in the dose optimisation studies of oncology drug. https://lnkd.in/ewRJXscS